These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 39351232)
1. Comprehensive analysis of stearoyl-coenzyme A desaturase in prostate adenocarcinoma: insights into gene expression, immune microenvironment and tumor progression. Wang J; Ying L; Xiong H; Zhou DR; Wang YX; Che HL; Zhong ZF; Wu GS; Ge YJ Front Immunol; 2024; 15():1460915. PubMed ID: 39351232 [TBL] [Abstract][Full Text] [Related]
2. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications. Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342 [TBL] [Abstract][Full Text] [Related]
3. Systematic analysis of fatty acid desaturases in breast invasive carcinoma: The prognosis, gene mutation, and tumor immune microenvironment. Wang J; Zhang Q; Zhou D; Wang Y; Che H; Ge Y; Zhong Z; Wu G Medicine (Baltimore); 2024 Jun; 103(25):e38597. PubMed ID: 38905386 [TBL] [Abstract][Full Text] [Related]
4. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Moore S; Knudsen B; True LD; Hawley S; Etzioni R; Wade C; Gifford D; Coleman I; Nelson PS Int J Cancer; 2005 Apr; 114(4):563-71. PubMed ID: 15609334 [TBL] [Abstract][Full Text] [Related]
5. Single-cell and bulk RNA-sequencing reveals mitosis-involved gene HAUS1 is a promising indicator for predicting prognosis and immune responses in prostate adenocarcinoma (PRAD). Liu S; Yu Y; Xu J; Wang Y; Li D Cell Biol Int; 2024 Aug; 48(8):1169-1184. PubMed ID: 38818762 [TBL] [Abstract][Full Text] [Related]
6. Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation. Kim SJ; Choi H; Park SS; Chang C; Kim E Mol Cells; 2011 Apr; 31(4):371-7. PubMed ID: 21331774 [TBL] [Abstract][Full Text] [Related]
7. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma. Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556 [TBL] [Abstract][Full Text] [Related]
8. Leveraging cell death patterns to predict metastasis in prostate adenocarcinoma and targeting PTGDS for tumor suppression. Chen B; Guo L; Wang L; Wu P; Zheng X; Tan C; Xie N; Sun X; Zhou M; Huang H; Hao N; Lei Y; Yan K; Wu D; Du Y Sci Rep; 2024 Sep; 14(1):21680. PubMed ID: 39289451 [TBL] [Abstract][Full Text] [Related]
9. Depiction of tumor stemlike features and underlying relationships with hazard immune infiltrations based on large prostate cancer cohorts. Zhang C; Chen T; Li Z; Liu A; Xu Y; Gao Y; Xu D Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32856039 [TBL] [Abstract][Full Text] [Related]
10. Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma. Sun X; Wang L; Li H; Jin C; Yu Y; Hou L; Liu X; Yu Y; Yan R; Xue F Aging (Albany NY); 2021 Jun; 13(12):16024-16042. PubMed ID: 34133324 [TBL] [Abstract][Full Text] [Related]
11. Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms. Liang W; Yang X; Li X; Wang P; Zhu Z; Liu S; Xu D; Zhi X; Xue J Aging (Albany NY); 2024 May; 16(9):7596-7621. PubMed ID: 38742936 [TBL] [Abstract][Full Text] [Related]
12. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma. Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262 [TBL] [Abstract][Full Text] [Related]
13. Exploring the interplay between bisphenol A exposure, the immune microenvironment and hepatocellular carcinoma progression. Liu Q; Niu R; Ye Y; Li J J Gene Med; 2024 Sep; 26(9):e3723. PubMed ID: 39228142 [TBL] [Abstract][Full Text] [Related]
14. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma. Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112 [TBL] [Abstract][Full Text] [Related]
15. Construction of store-operated calcium entry-related gene signature for predicting prognosis and indicates immune microenvironment infiltration in stomach adenocarcinomas. Zhang Z; Wang C; Shi W; Wang Z; Fu W Sci Rep; 2024 Sep; 14(1):22342. PubMed ID: 39333689 [TBL] [Abstract][Full Text] [Related]
16. Prostate adenocarcinoma and COVID-19: The possible impacts of TMPRSS2 expressions in susceptibility to SARS-CoV-2. Cheng J; Zhou J; Fu S; Fu J; Zhou B; Chen H; Fu J; Wei C J Cell Mol Med; 2021 Apr; 25(8):4157-4165. PubMed ID: 33609069 [TBL] [Abstract][Full Text] [Related]
17. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma. Xu Z; Chen S; Zhang Y; Liu R; Chen M Front Immunol; 2022; 13():869759. PubMed ID: 35603206 [TBL] [Abstract][Full Text] [Related]
18. The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma. Wang H; Zhang Y; Lu Y; Song J; Huang M; Zhang J; Huang Y Tumour Biol; 2016 Jan; 37(1):479-89. PubMed ID: 26224474 [TBL] [Abstract][Full Text] [Related]
19. Construction of lncRNA/Pseudogene-miRNA Network Based on In Silico Approaches for Glycolysis Pathway to Identify Prostate Adenocarcinoma-Related Potential Biomarkers. Khorsand M; Mostafavi-Pour Z; Tahmasebi A; Omidvar Kordshouli S; Mousavi P Appl Biochem Biotechnol; 2024 Apr; 196(4):2332-2355. PubMed ID: 37542606 [TBL] [Abstract][Full Text] [Related]
20. The prognostic value and potential subtypes of immune activity scores in three major urological cancers. Shi B; Qi J J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]